Advertisement

Dosierung von Neuroleptika

  • S. Sieberns
Conference paper

Zusammenfassung

Seit der Einführung der Neuroleptika 1952 wurde eine große Anzahl psychotischer Patienten neuroleptisch behandelt. Trotzdem ist die Frage, in welcher Dosierung Neuroleptika im Einzelfall anzuwenden sind, noch immer nicht ausreichend wissenschaftlich begründet zu entscheiden (McIntyre u. Gershon 1985).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Baldessarini RJ, Davis JM (1980) What is the best maintenance dose of neuroleptics in schizophrenia. Psychiatry Res 3:115–122PubMedCrossRefGoogle Scholar
  2. Bjørndal N, Bjerre M, Gerlach J, Kristjansen P, Magelund G, Oestrich IH, Waehrens J (1980) High dosage haloperidol therapy in chronic schizophrenic patients: A double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin. Psychopharmacology 67:17–23PubMedCrossRefGoogle Scholar
  3. Carpenter W (1986) Early targeted pharmacotherapeutic intervention in schizophrenia. J Clin Psychiatry 47:23–29PubMedGoogle Scholar
  4. Cheeseman HJ, Neal MJ (1981) Interaction of chlorpromazine with tea and coffee. Br J Pharmacol 12:165–169Google Scholar
  5. Chouinard G (1982) Neuroleptic-induced supersensitivity psychosis. In: De Veaugh-Geis J (eds) Tardive dyskinesie and related involuntary movement disorders. John Wright, BostonGoogle Scholar
  6. Dahl SG (1976) Pharmacokinetics of methotrimeprazine after single and multiple doses. Clin Pharmacol Ther 19:435–442PubMedGoogle Scholar
  7. Delay J, Deniker P (1971) Méthodes chimicothérapiques en psychiatric Les nouveaux médicaments psychotropes, Vol 1. Masson, Paris, p 189Google Scholar
  8. Dencker SJ, Enoksson P, Johansson R, Lundin L, Malm U (1981) Late (4–8 years) outcome of treatment with megadoses of fluphenazine enanthate in drug-refractory schizophrenics. Acta Psychiatr Scand 63:1–12PubMedCrossRefGoogle Scholar
  9. Donlon PT (1976) High dosage neuroleptic therapy. Int Pharmacopsychiatry 11:235–245PubMedGoogle Scholar
  10. Donlon PT, Tupin JP (1974) Rapid ‘digitalization’ of decompensated schizophrenic patients with anti-psychotic agents. Am J Psychiatry 131:310–312PubMedGoogle Scholar
  11. Extein J, Augusthy KA, Gold MS et al. (1982) Plasma haloperidol levels and clinical response in acute schizophrenia. Psychopharmacol Bull 21:59–61Google Scholar
  12. Forsman A, Öhman R (1976) Pharmacokinetic studies on haloperidol in man. Curr Ther Res 20:319–336PubMedGoogle Scholar
  13. Gardos G, Cole JO, Orzack MH (1973) The importance of dosage in antipsychotic drug administration. Psychopharmacologia 29:221–230PubMedCrossRefGoogle Scholar
  14. Hansen CE, Christensen TR, Elley J et al. (1976) Clinical pharmacokinetic studies of perphenazine. Br J Clin Pharmacol 3:915–923Google Scholar
  15. Hogarty GE (1984) Depotneuroleptics: The relevance of psychosocial factors — a United States prospective. J Clin Psychiatry 45:36–42PubMedGoogle Scholar
  16. Hyttel J (1978) A comparison of the effect of neuroleptic drugs on the binding of 3H-haloperidol and 3H-cis(Z)-flupenthixol and on adenylate cyclase activity in rat striatal tissue in vitro. Prog Neuro-Psychopharmacol Biol Psychiatry 2:329–335Google Scholar
  17. Hyttel J (1982) Preferential labelling of adenylate cyclase coupled dopamine receptors with thioxanthene neuroleptics. In: Kohsaka M et al. (eds) Advances in the biosciences, advances in dopamine research. Pergamon Press, OxfordGoogle Scholar
  18. Hyttel J, Christensen AV, Arnt J, Svendsen O (1983) Neuroleptics. New experimental findings on receptor mechanisms, antipsychotic effect and dyskinesia. Clopixol-Symposion. Eigenverlag, Lundbeck AG ZürichGoogle Scholar
  19. Jenner P (1986) Dopamine D-1 and D-2 receptor in brain — clinical implication. In: Rafaelsen OJ, Christensen AB (eds) What can basic biological do for the treatment of acute psychosis? Eigenverlag, Lundbeck AG KopenhagenGoogle Scholar
  20. Johnson DAW (1984) Observations on the use of long-acting depotneuroleptic injections in the maintenance therapy of schizophrenia. J Clin Psychiatry 5:13–21Google Scholar
  21. Jørgensen A (1980) Pharmacokinetic studies in volunteers of intravenous and oral cis(Z)-flupentixol and intramuscular cis(Z)-flupentixoldecanoate in viscoleo. Eur J Clin Pharmacol 18:355–360PubMedCrossRefGoogle Scholar
  22. Kane JM (1984) Dosage reduction strategies in the long-term treatment of schizophrenia. In: Kane JM (ed) Drug maintenance strategies in schizophrenia. American Psychiatric Press, Washington, D.C.Google Scholar
  23. Kane JM, Rifkin A, Quitkin F et al. (1979) Low dose fluphenazine decanoate in maintenance treatment of schizophrenia. Psychiatry Res 1:341–348PubMedCrossRefGoogle Scholar
  24. Kane JM, Rifkin A, Quitkin F et al. (1982) Fluphenazine vs. placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry 39:70–73PubMedCrossRefGoogle Scholar
  25. Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, Ramos-Lorenzi J (1983) Low-dose neuroleptic treatment of outpatient schizophrenics. Arch Gen Psychiatry 40:893–896PubMedCrossRefGoogle Scholar
  26. Kane JM, Woerner M, Sarantakos S (1986) Depot neuroleptics: A comparative review of standard, intermediate, and low-dose regimens. J Clin Psychiatry 47:30–33PubMedGoogle Scholar
  27. Labhardt FD (1954) Largactiltherapie bei Schizophrenien und anderen psychotischen Zuständen. Schweiz Arch Neurol Neurochir Psychiatr 73:309Google Scholar
  28. Lasswell WL, Weber SS, Wilkins JM (1984) In vitro interaction of neuroleptics and tricyclic antidepressants with coffee, tea, and gallotannic acid. J Pharmacol Sci 73:1056–1058CrossRefGoogle Scholar
  29. Ljungberg T (1986) The dopamine theory — Where are we today? In: Rafaelsen OJ, Christensen AV (eds) What can basic biological do for the treatment of acute psychosis? Eigenverlag, Lundbeck AG KopenhagenGoogle Scholar
  30. Magliozzi J, Hollister LE, Arnold KV et al. (1981) Relationship of serum haloperidol levels to clinical response in schizophrenic patients. Am J Psychiatry 138:365–367PubMedGoogle Scholar
  31. Malm U, Dencker SJ (1980) Die Behandlung von akuten Psychosen mit Flupenthixol. In: Kryspin-Exner K, Hinterhuber H, Schubert H (Hrsg) Therapie akuter psychiatrischer Syndrome. Schattauer, StuttgartGoogle Scholar
  32. Marder SR, Putten T van, Mintz J et al. (1984) Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 41:1025–1029PubMedCrossRefGoogle Scholar
  33. Mavroidis ML, Hirschowitz J, Kenter J et al. (1983) Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology 81:354–356PubMedCrossRefGoogle Scholar
  34. McCreadie RG, Mackie M, Wiles DH, Jørgensen A, Hansen V, Mezies C (1984) Within-individual variation in steady state plasma levels of different neuroleptics and prolactin. Br J Psychiatr 144:625–629CrossRefGoogle Scholar
  35. McIntyre IM, Gershon S (1985) Interpatient variations in antipsychotic therapy. J Clin Psychiatry 46:3–5PubMedGoogle Scholar
  36. Mikkelsen EJ (1978) Caffeine and schizophrenia. J Clin Psychiatry 39:732–736PubMedGoogle Scholar
  37. Miller DJ, Hershey LA, Duffy JP et al. (1984) Serum haloperidol concentrations and clinical response in acute psychosis. J Clin Psychopharmacol 4:305–310PubMedCrossRefGoogle Scholar
  38. Müller H (1962) Die Bedeutung der Psychotonika für die Praxis. Prakt Arzt 16:323Google Scholar
  39. Neborsky R, Janowsky D, Munson E, Depry D (1981) Rapid treatment of acute psychotic symptoms with high- and low-dose haloperidol. Arch Gen Psychiatry 38:195–199PubMedCrossRefGoogle Scholar
  40. Ortiz A, Gershon S (1986) The future of neuroleptic psychopharmacology. J Clin Psychiatry 47:5(Suppl)Google Scholar
  41. Platz T, Hinterhuber H (1981) Die hochdosierte Neuroleptikatherapie. Pharmacopsychiatria 14:141–147PubMedCrossRefGoogle Scholar
  42. Potkin SG, Shen Y, Zhou S et al. (1985) Does a therapeutic window for plasma haloperidol exist? Preliminary Chinese data. Psychopharmacol Bull 21:59–61PubMedGoogle Scholar
  43. Putten T van, Marder SR (1986) Low-dose treatment strategies. J Clin Psychiatry 47:12–16PubMedGoogle Scholar
  44. Richelson E (1984) Neuroleptic affinities for human brain receptors and their use in predicting adverse effect. J Clin Psychiatry 45:331–336PubMedGoogle Scholar
  45. Richelson E (1985) Pharmacology of neuroleptics in use in the United States. J Clin Psychiatry 46:8–14PubMedGoogle Scholar
  46. Rimón R, Averbuch I, Rozick P et al. (1981) Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients. Psychopharmacology 73:197–199PubMedCrossRefGoogle Scholar
  47. Sieberns S (1986) Akut-Behandlung schizophrener Psychosen mit Benperidol. Krankenhausarzt 59:925–930Google Scholar
  48. Smith RC, Baumgartner R, Burd A et al. (1985) Haloperidol and thioridazin drug levels and clinical response in schizophrenia: Comparison of gas-liquid chromatography and radioreceptor drug level assays. Psychopharmacol Bull 21:52–58PubMedGoogle Scholar
  49. Smith RC, Baumgartner R, Misra CH et al. (1984) Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: Chemical vs. radioreceptor plasma assays. Arch Gen Psychiatry 41:1044–1049PubMedCrossRefGoogle Scholar
  50. Smith RC, Vroulis G, Shvartsburd A et al. (1983) RBC and plasma levels and clinical response in schizophrenia. Am J Psychiatry 139:1054–1056Google Scholar
  51. Staehelin JE, Kielholz P (1953) Largatil, ein neues vegetatives Dämpfungsmittel bei psychischen Störungen. Schweiz Med Wochenschr 25:581Google Scholar
  52. Tegeler J, Lehmann E, Quadbeck H et al. (1982) Experimenteller Vergleich niedriger und hoher Haloperidol-Dosen in der Behandlung akut schizophrener Patienten. Arzneimittelforsch 32:887–888Google Scholar
  53. Tischio J, Hetyei N, Patrick J, Killinger J (1981) Determination of bromperidol in human plasma by radioimmunoassay (RIA) methodology. Clin Chem Abstr 27:403Google Scholar
  54. Tune LE (1980) Haloperidol drug level monitoring: Pharmacokinetic and methodologic considerations with special emphasis on radioreceptor assay techniques. In: Ayd FJ (eds) Haloperidol update: 1958–1980. Ayd Medical Communications, Baltimore, Md.Google Scholar
  55. Ungerstedt U, Herrera-Marschitz M, Forster C (1985) Neuroleptic drugs and their action of different neuronal pathways. J Clin Psychiatry 46:34–37PubMedGoogle Scholar
  56. Wiesel FA, Alfredsson G, Ehrnebo M, Sedvall G (1980) The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. Eur J Clin Pharmacol 17:385–391PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • S. Sieberns

There are no affiliations available

Personalised recommendations